2013美国心脏病学会/美国心脏学会(ACC/AHA)血脂管理指南自发布伊始,就引发了大量的关注和争论,其核心焦点就是该指南创新性地提出抛弃沿用已久的血脂管理目标水平,而采用他汀治疗的强度,即血脂下降的幅度来评估他汀治疗是否已经达到“足剂量”。有识之士曾指出,这一举措可能会是“疾病预防史上巨大的模式转换”过程,但同时专家也认为,如何使得医务人员放弃原本对于血脂管理目标值的认知,接受根据他汀治 2013 The American Heart Association / American Heart Association (ACC / AHA) guidelines for lipid management have generated a great deal of attention and debate since their debut, with a core focus being that the guidelines innovatively address the long-awaited goal of lipid management, Instead, the strength of statin therapy, the magnitude of the decline in lipids, is used to assess whether statin therapy has reached a “full dose.” Some people of insight have pointed out that this move may be “a huge paradigm shift in the history of disease prevention,” but at the same time, experts also think that how to make medical staff abandon their original understanding of the target value of blood lipid management and accept the statin rule